Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

ByLois C

Apr 5, 2022 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

ROCKVILLE, Md., March 31, 2022–(Business enterprise WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held medical-stage biotechnology corporation pioneering the examine of LAMP-mediated nucleic acid-based mostly immunotherapy announced now that the corporation will be presenting two posters at the American Affiliation for Cancer Research (AACR) Annual Conference 2022 getting held in New Orleans, Louisiana, from April 8-13. The posters to be introduced at AACR are designed from the investigational nucleic acid platform, UNITE™ (Universal Intracellular Targeted Expression) for two vaccines, ITI-3000 for Merkel cell carcinoma and Her2/Neu-LAMP DNA vaccine, each which fuse a tumor affiliated antigen with lysosomal connected membrane protein 1 (LAMP-1). This proprietary lysosomal concentrating on technological know-how benefits in improved antigen presentation and a balanced T mobile response.

“Both ITI-3000 and Her2/Neu-LAMP DNA vaccines are impressive and novel targeted techniques,” says Teri Heiland, Ph.D., Immunomic’s Chief Scientific Officer. “We are extremely encouraged by the details and appear forward to a 1st-in-human demo for ITI-3000, a vaccine for Merkel cell carcinoma, and further pre-medical growth for Her2/Neu-LAMP vaccine.”

Poster Title: LAMP1 targeting of the significant T antigen of Merkel mobile polyomavirus elicits strong CD4+ T mobile responses, tumor inhibition, and delivers rationale for initial-in-human demo

Session Classification: Immunology

Session Title: Immune Reaction to Therapies 1

Session Date and Time: Monday April 11, 2022, 1:30 PM – 5:00 PM ET

Location: New Orleans Convention Middle, Exhibit Halls D-H, Poster Section 37

Poster Range: 10

—————————————————————————————————————————————–

Poster Title: Harnessing soluble CD40L to enrich anti-tumor efficacy of Her2-LAMP DNA vaccine working with UNITE™ platform

Session Classification: Immunology

Session Title: Vaccines: Oncolytic and Prophylactic

Session Date and Time: Tuesday April 12, 2022, 1:30 PM – 5:00 PM ET

Locale: New Orleans Convention Centre, Show Halls D-H, Poster Section 40

Poster Variety: 3

Poster Availability: e-Posters will be on show in the AACR Gallery

About UNITE

ITI’s investigational UNITE platform, Common Intracellular Focused Expression, leverages the skill to engineer chimeric proteins, directing antigen presenting cells to existing antigens to the immune process through a focused pathway and driving a sturdy immune reaction. UNITE vaccines are distinctive in that they merge two factors: nucleic acid constructs that encode a distinct antigen and an endogenous Lysosomal Associated Membrane Protein (LAMP-1) sequence. The UNITE platform harnesses LAMP-1 as a signifies of presenting the vaccine goal to the immune technique, resulting in antibody creation, inflammatory cytokine release, and establishing significant immunological memory, a little something that other vaccine techniques typically deficiency. This strategy could put UNITE technologies at the crossroads of immunotherapies in a number of indications, including most cancers, human allergy, animal well being, and infectious condition. Preclinical data is currently getting made to take a look at irrespective of whether LAMP-1 nucleic acid constructs may amplify and activate the immune response in very immunogenic tumor forms and applied to create immune responses in tumor types that normally do not provoke an immune reaction.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical phase biotechnology corporation pioneering the development of vaccines as a result of its proprietary know-how platform, Common Intracellular Focused Expression (UNITE), which is made to benefit from the body’s organic biochemistry to acquire vaccines that generate broad immune responses. UNITE has a sturdy historical past of purposes in various therapeutic spots, which include infectious disorders, oncology, allergy, and autoimmune health conditions. ITI is primarily centered on making use of the UNITE system to oncology, wherever it could potentially have wide applications, including antigen-derived antibodies as biologics. The Company has constructed a pipeline leveraging UNITE with programs in oncology, animal wellbeing, infectious disorder, and allergy. ITI maintains its headquarters in Rockville, Maryland. For far more facts, please go to www.immunomix.com.

View resource version on businesswire.com: https://www.businesswire.com/information/dwelling/20220331005007/en/

Contacts

Corporation:
Melissa Kemp
[email protected]
301-968-3501

ITI Media:
Melody Carey
[email protected]
917-322-2571

By Lois C